For the quarter ending 2026-03-31, COCP had -$2,340K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -2,299 | -2,426 | -2,049 | -4,356 |
| Depreciation and amortization expense | 12 | 13 | 13 | 46 |
| Right of use assets | - | 304 | - | - |
| Stock-based compensation | 84 | 56 | 48 | 166 |
| Decrease right of use assets | -147 | - | 226 | - |
| Grant receivable | 70 | - | - | - |
| Change in operating lease liabilities | - | 301 | - | - |
| Prepaid expenses and other current assets | 90 | -198 | 244 | -148 |
| Tax credit receivable | -15 | 193 | -1,129 | 427 |
| Deposits | - | 7 | - | 59 |
| Accounts payable and accrued expenses | 10 | 682 | -320 | -613 |
| Decrease in right of use assets | - | - | - | 149 |
| Operating lease liabilities | 142 | - | -75 | -148 |
| Net cash used in operating activities | -2,340 | -1,736 | -1,362 | -5,094 |
| Purchases of property and equipment | - | 0 | 12 | 0 |
| Net cash used in investing activities | - | 0 | -12 | 0 |
| Proceeds from the sale of common stock under atm | - | 0 | 154 | - |
| Proceeds from sale of common stock and warrants, net of transaction costs | - | 1,032 | 4,183 | - |
| Net cash provided by financing activities | - | 1,032 | 4,337 | - |
| Net decrease in cash and restricted cash | -2,340 | -704 | 2,963 | -5,094 |
| Cash and restricted cash at beginning of period | 7,100 | 7,804 | 9,935 | - |
| Cash and restricted cash at end of period | 4,760 | 7,100 | 7,804 | - |
Cocrystal Pharma, Inc. (COCP)
Cocrystal Pharma, Inc. (COCP)